logo

Galectin Therapeutics Inc (GALT)



Trade GALT now with
  Date
  Headline
9/20/2018 8:04:32 AM Galectin Therapeutics Announces Positive Preliminary Results From Phase 1b Clinical Trial Of GR-MD-02 And KEYTRUDA
8/14/2018 8:08:17 AM Galectin Therapeutics Q2 Loss Applicable To Stockholders $4.1 Mln Or $0.11/Shr Vs Loss $4.8 Mln Or $0.14/Shr Last Year
6/27/2018 8:05:38 AM Galectin Therapeutics Receives Patent For GR-MD-02 Patent For Method And Treatment Of Pulmonary Fibrosis
6/12/2018 8:37:23 AM Galectin Therapeutics Names Harold Shlevin CEO And President To Succeed Peter Traber
6/4/2018 9:13:19 AM Galectin Therapeutics Elects Richard Uihlein As Chairman Of Board Of Directors
5/14/2018 9:05:50 AM Galectin Proceeds To Phase 3 Development Of GR-MD-02 For NASH Cirrhosis Following FDA Meeting
5/11/2018 4:26:11 PM Galectin Therapeutics Q1 Loss/share $0.12 Vs. Loss $0.15 Year Ago
3/29/2018 8:14:07 AM Galectin Therapeutics FY Net Loss Applicable To Common Stockholders $17.5 Mln Or $0.49 Per Share
1/25/2018 8:37:34 AM Galectin Receives Patents In China And Japan That Support NASH And Cancer Immunotherapy Clinical Development Programs